Clinical Trial Update: An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases [Phase 1, Phase 2]

View source ↗

Summary

An open-label Phase 1/2 study evaluating povetacicept in autoantibody-associated glomerular diseases is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Iga Nephropathy
• Lupus Nephritis
• Membranous Nephropathy

Drugs mentioned

• Povetacicept (povetacicept)

Snippet

Sponsor: Alpine Immune Sciences, Inc. | Conditions: Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING